Effects of treatment regimens on survival in patients with malignant pleural mesothelioma

Transcription

1 European Review for Medical and Pharmacological Sciences Effects of treatment regimens on survival in patients with malignant pleural mesothelioma A. ABAKAY 1, O. ABAKAY 2, A.C. TANRIKULU 1, C. SEZGI 1, H. SEN 1, H. KAYA 1, M. KUCUKONER 2, M.A. KAPLAN 3, Y. CELIK 4, A. SENYIGIT ; 17: Department of Chest Disease, 3 Department of Medical Oncology and 4 Department of Biostatistics; School of Medicine, Dicle University, Diyarbakir, Turkey 2 Department of Chest Disease, Education and Training Hospital, Diyarbakir, Turkey Abstract. BACKGROUND AND OBJECTIVE: In this study, we aimed to investigate the factors affecting the survival of patients with malignant pleural mesothelioma (MPM) according to their treatment regimens, including best supportive care (BSC), chemotherapy, surgical group and multimodality (MM) therapy. PATIENTS: A retrospective analysis was performed on clinical data and treatment outcomes of 400 patients registered in our hospital with MPM between January 1989 and April RESULTS: Mean age (p < 0.001), presence of asbestos exposure (p = ), presence of smoking history (p < 0.001), Karnofsky performance status (p < 0.001), histological subtype (p = 0.034) and stage (p < 0.001) variables were found to be significantly different among the four treatment regimens. Mean survival time of all patients was months. Mean survival time 10.5 months for the BSC group, 15.7 for the surgical group, for the chemotherapy group, and for the MM group. There were significant differences in mean survival time among the four treatment regimens. In addition, a significant difference was found in survival time between the two chemotherapy groups (p = 0.032). Mean survival time for cisplatin + gemcitabine was found to be months and for cisplatin + pemetrexed, months. CONCLUSIONS: The MM group had better survival rates than the other groups. The new chemotherapy combination, cisplatin + pemetrexed, can be helpful in improving survival time. Key Words: Mesothelioma, Survival, Treatment, Prognosis. Introduction Malignant mesothelioma is a cancer originating in the pleura, pericardium, and peritoneum or tunica vaginalis; since the early 1960s, its relation to asbestos exposure has been very well recognized 1. Asbestos exposure can be environmental or occupational. Moreover, erionite, a natural fibrous zeolite, which can be found in volcanic tuff, has been found to in- duce malignant pleural mesothelioma (MPM). MPM due to both asbestos and erionite environmental exposure is a relatively common cancer in Turkey 2. MPM remains a fatal cancer despite improvements in treatment and still has increasing incidence associated with asbestos exposure 3. Individual patients might respond to chemotherapy, radiotherapy or immunotherapy, and selected patients, especially in early stages, might benefit from radical surgery and multimodality (MM) treatment 4. Although it is claimed that MM regimens prolong survival only slightly and for relatively few patients in whom it is possible to perform radical surgery 4,5, most patients have unresectable disease at presentation, and systemic therapy is the only treatment option for them 7. The best treatment for MPM is trimodality therapy, consisting of extrapleural pneumonectomy (EPP), neoadjuvant or adjuvant chemotherapy, and adjuvant high-dose hemithoracic radiotherapy. Trimodality therapy has been reported to offer longterm survival in selected patients with MPM 8. The MM treatment has achieved a median survival of 19 to 46 months, depending on the stage, histology, and completeness of the surgical resection In Turkey, few reports have been published about survival and MM treatment. Most of the studies published are about MPM epidemiology, and clinical and radiological features In this study, we aimed to investigate the characteristics of the several variables affecting the survival of patients with MPM according to their treatment schedules, including best supportive care (BSC), surgical treatment, chemotherapy, and MM treatment in a University Hospital setting. Materials and Methods Patients Asbestos exposure is common in the southeast region of Turkey, and incidence of asbestos-related Corresponding Author: Abdurrahman Abakay, MD; 19

2 A. Abakay, O. Abakay, A.C. Tanrıkulu, C. Sezgi, H. Sen, H. Kaya, et al. diseases is high there Most of our patients had been subjected to environmental exposure. The time period between the first asbestos exposure and diagnosis is described as the latent period. A retrospective analysis was performed on clinical data and treatment outcomes of 400 patients registered in our Hospital with malignant pleural mesothelioma (MPM) between January 1989 and April Histologyproven MPM patients were included in the study. The local Ethical Committee approved the study protocol. Because some patients did not allow thoracoscopy, Butchart et al staging system was used after histopathological diagnosis 16. Thoracal and abdominal computed topographies (CT) were done, and cranial CT was done if necessary. These CT scans were evaluated by a radiological specialist. Criteria were age ( 60 years or >60), gender, asbestos exposure (yes or no), primary site of disease (right, left, bilateral), histopathological subtype (epithelial or other), smoking history (yes or no), Karnofsky performance score (KPS) ( 60 or >60), presence of dyspnea, weight loss (more than 5% in last three months) and stage (stage I-II or stage III-IV). The patients were classified into four groups according to their treatment schedule: the best supportive care (BSC) group, which consisted of patients with low performance status and who were not suitable for other treatment options (266 patients); the chemotherapy group (100 patients); the surgical group (18 patients); and the multimodality (MM) therapy group (16 patients). In the surgical group, decortication of visceral and parietal pleura was performed with BSC. This group of patients was not eligible for other treatment options. All chemotherapy was given at our Chemotherapy Unit between 1990 and 2005 as cisplatin (75 mg/m 2 1 day) + gemcitabine (1250 mg/m 2 1 and 8 day schedules) (45 patients) and after 2005 as cisplatin (75 mg/m 2 ) + pemetrexed (500 mg/m 2 ) (55 patients). In the MM group, surgical resection consisted of extrapleural pneumonectomy (EPP) with resection of the lung, parietal pleura, hemipericardium and diaphragm. A systematic hilar and mediastinal lymphadenectomy was conducted. The diaphragm and pericardium were reconstructed using mesh. Adjuvant radiotherapy was delivered to the hemithorax, the thoracotomy incision, and at the sites of chest drains. The chemotherapy protocol for the entire MM group was cisplatin (75 mg/m 2 ) + pemetrexed (500 mg/m 2 ). Statistical Analysis Mean and standard deviation (SD) were calculated for continuous variables. The normality of the variables was analyzed by Kolmogorov- Smirnov test. For the purpose of analysis, oneway ANOVA test was used as appropriate. Pearson s Chi-Square (χ 2 ) test was used to evaluate associations between the categorical variables. Logistic Regression (LR) analysis was performed in order to determine the risk variables of MPM. Odd s ratios were also calculated by LR. All variables were included in the backward stepwise procedure. Kaplan-Meier survival curves were used to find the survival time of BSC, chemotherapy, surgical and MM therapy groups. Survival curves for the cisplatin + gemcitabine and for the cisplatin + pemetrexed therapy groups were also determined. The differences among survival curves were found by using Log Rank Analysis (Mantel-Cox). Two-sided p values were considered statistically significant at p < Statistical analyses were carried out by using the statistical packages for SPSS 15.0 for Windows (SPSS Inc., Chicago, IL, USA). Results The mean age of patients (n=400) was ± (19-85) years. There were 236 male patients (59%) and 164 (41%) female patients. Eighty-six percent of patients had environmental asbestos exposure, and mean duration of asbestos exposure was found to be ± years. The mean latent period of patients with a history of exposure was 45.2 ± 12.2 years. Mean Karnofsky performance score (KPS) was (50-80). Of the 400 patients in this study, 285 (71.2%) were diagnosed by non-invasive pleural biopsy and 115 (28.8%) were diagnosed by surgical pleural biopsy. The average sedimentation value of patients was 69.7 ± 21.9 mm/hour. Average survival time of all patients after diagnosis was calculated to be 12.3 ± 8.6 (1-53) months. Median follow up was 13 months. As determined by univariate analysis in the 400 patients, poor prognosis was associated with the presence of smoking history (p < 0.007; 9.0 versus 10.5 months), a poor KPS (p < 0.001; 7.0 versus 15.0 months), a nonepithelial histology subtype (p < 0.018; 8.0 versus 11.0 months), and stage III-IV disease (p < 0.000; 7.0 versus 14.0 months). Characteristics of the patients according to their treatment groups are presented in Table I. The mean 20

5 Effects of treatment regimens on survival in patients with malignant pleural mesothelioma while it was 9.3 months for cisplatin, and this difference was statistically significant 26. We presented survival series in Table III, but in these series, we generally used older chemotherapeutic agents. The main limitation for this study is that this was not a randomized trial; therefore, patient characteristics, especially comorbidities, varied. Conclusions Figure 2. Kaplan-Meier survival curves for the cisplatin + gemcitabine and the cisplatin + pemetrexed therapy group. Patients who received MM treatment were younger, their KPS was higher, and they were at earlier stages in the disease when compared with the other treatment groups. Patients in the MM treatment group also had better survival times than other treatment groups, potentially due to lower patient age, better performance status and lower clinical stage. In an earlier study conducted in Turkey, MPM patients receiving MM therapy, who had stage I-II, epithelial types and earlier ages, had better survival rates than other groups 25. Thus, age, histopathological type of MPM, KPS and stage are very important prognostic factors for planning the treatment after the diagnosis. The chemotherapy group had better survival than the BSC group. Patients who received cisplatin + pemetrexed after 2005 had a mean survival of months. We determined that better survival in the chemotherapy group is associated with this new combination. In a study comparing cisplatin + pemetrexed with cisplatin alone in patients with MPM, mean survival in the cisplatin + pemetrexed group was found to be 12.1 months, Malignant pleural mesothelioma (MPM) is remains a fatal prognosis. We investigated the various pretreatment clinical and laboratory characteristics affecting the survival of patients with MPM according to their treatment schedules. The MM treatment group had better survival rates than the other groups. However, the new chemotherapy combination cisplatin + pemetrexed can be helpful for improving survival time of MPM. Henceforth, priority should be given to studies which will determine clinical and biochemical markers that may help to identify patients who will benefit from these treatment options. References 1) WAGNER JC, SLEGGS CA, MARCHAND P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Indust Med 1960; 17: ) SELCUK ZT, COPLU L, EMRI S, KALYONCU AF, SAHIN AA, BARIŞ YI. Malignant pleural mesothelioma due to environ mental mineral fiber exposure in Turkey. Analysis of 135 cases. Chest 1992; 102: ) PETO J, DECARLI A, LA VECCHIA C, LEVI F, N EGRI E. The European mesothelioma epidemic. Br J Cancer 1999; 79: ) BURGERS JA, DAMHUIS RAM. Prognostic factors in malignant mesothelioma. Lung Cancer 2004; 45: ) SUGARBAKER DJ, JAKLITSEH MT, LIPTAY MJ. Mesothelioma and radical multimodality therapy: who benefits? Chest 1995; 107: Table IV. Distribution of treatment groups of patients for 5 year intervals. BSC CT Surgical MM Years n % n % n % n % Total

Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are

The incidence of mesothelioma has not decreased for the last twenty years in Southeast region of Anatolia Carkanat AI 1, *Abdurrahman A 1, Abakay O 2, Cengizhan S 1, Selimoglu SH 1, Senyigit A 1 1. Department

Malignant Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)

Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)

Report on New Patented Drugs - Alimta Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB s Excessive

For media outside the US, UK and Canada only P L E U R A L M E S O T H E L I O M A 1. Overview 2. What is pleural mesothelioma? 3. How common is pleural mesothelioma? 4. What are the risk factors for pleural

Clinical Report The value of inflammatory parameters in the prognosis of malignant mesothelioma Journal of International Medical Research 2014, Vol. 42(2) 554 565! The Author(s) 2014 Reprints and permissions:

Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell

Lung Cancer and Mesothelioma Robert Kratzke, M.D. John C. Skoglund Professor of Lung Cancer Research Section of Heme/Onc/Transplant Department of Medicine University of Minnesota Medical School Malignant

55 Treatment of Malignant Pleural Mesothelioma: Is There a Benefit to Pleuropneumonectomy? Stacey Su, Michael T. Jaklitsch, and David J. Sugarbaker Malignant pleural mesothelioma (MPM) is a rare but highly

The research and development and the dissemination projects related to the 13 fields of occupational injuries and illnesses Survey of Mesothelioma Associated with Asbestos Exposure in Japan Clinical characteristics

Lessons learned from the Western Australian experience with mesothelioma Alison Reid, Western Australian Institute for Medical Research In partnership with Nick de Klerk, Nola Olsen, Jan Sleith, Geoffrey

Introduction Objective Methods Results Conclusion 2 Malignant pleural mesothelioma (MPM) is the most common form of mesothelioma a rare cancer associated with long latency period (i.e. 20 to 40 years),

Chapman E, García Diéguez M This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2010, Issue 4 http://www.thecochranelibrary.com

PET/CT Imaging in Lung Cancer Mylene T. Truong, MD Mylene T. Truong M.D. Objectives To discuss the role of PET/CT in the staging of lung cancer To review the recommendations from American Society of Clinical

Understanding Pleural Mesothelioma UHN Information for patients and families Read this booklet to learn about: What is pleural mesothelioma? What causes it? What are the symptoms? What tests are done to